Unknown NA INTERVENTIONAL 1-arm NCT01042717

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

Mobilization Kinetics of Plerixafor and G-CSF in Patients With NHL and MM Undergoing Autologous Peripheral Blood Progenitor Cell Collection

Sponsor: Genzyme, a Sanofi Company

Conditions Multiple Myeloma Non-Hodgkins Lymphoma

Interventions Plerixafor

Updated 6 times since 2017 Last updated: Sep 26, 2011 Started: Feb 28, 2010 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Multiple Myeloma and Non-Hodgkins Lymphoma, this trial is ongoing. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 6 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA
Feb 2017 — Jun 2018 [monthly]

Unknown Status NA

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status NA

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company
Shi, Patricia, M.D.

Data source: Shi, Patricia, M.D.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States